Groundbreaking stem cell therapy for multiple sclerosis recommended for use in Scotland

Groundbreaking stem cell therapy for multiple sclerosis recommended for use in Scotland

Publication date: Nov 05, 2019

An international clinical trial proved Haematopoietic stem cell transplantation (HSCT) could reboot MS patients’ immune systems and halt the progress of the disease.

An international clinical trial proved Haematopoietic stem cell transplantation (HSCT) could reboot MS patients’ immune systems and halt the progress of the disease.

Some patients who had been in wheelchairs prior to treatment said their condition improved so dramatically it was like they had never been diagnosed with MS. The Scottish Health Technologies Group (SHTG) said there is now sufficient evidence for it to recommend making HSCT available on the NHS in Scotland.

But the theory is that the treatment works by enabling patients to “reset” their immune system to stop it attacking the central nervous system – as is the case in MS. HSCT is not considered an effective treatment for patients with the progressive form of MS. However, as stem cells cannot regrow nerves or repair damaged myelin – the protective sheath coating nerves.

Morna Simpkins, director of MS Society Scotland, said: “The decision from SHTG to approve HSCT for the treatment of MS is good news and could help in the development of a clear pathway, for people who could potentially benefit, to access it.

Concepts Keywords
Bone Marrow MRI
Central Nervous System Chemotherapy
Chemotherapy Transplantation
Clinical Trial Faulty immune systems
Disability MS
Haematopoietic High risk infections
Immune System Chemotherapy
Inflammation Medical specialties
Israel Medicine
London Clinical medicine
Mexico Transplantation medicine
MRI Brain Scan Hematology
Multiple Sclerosis Lymphology
Myelin Surgical oncology
NHS Scotland HSCT
Progressive Multiple sclerosis
Reboot
Russia
Scotland
Scottish

Semantics

Type Source Name
gene UNIPROT SET
drug DRUGBANK Aspartame
disease MESH development
gene UNIPROT CYREN
disease MESH inflammation
disease DOID relapsing-remitting MS
gene UNIPROT MAP6
pathway BSID Immune System
disease MESH infections
gene UNIPROT PTPN5
disease MESH relapses
gene UNIPROT NHS
disease DOID multiple sclerosis
disease MESH multiple sclerosis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *